Innocan Pharma Corp (INNO.CN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 09-2024 | 06-2024 | 03-2024 | 12-2023 | 09-2023 | |
| Sales | 8,624 | 8,644 | 6,768 | 4,893 | 4,083 |
| Cost of Goods | 845 | 646 | 767 | 604 | 419 |
| Gross Profit | 7,779 | 7,998 | 6,001 | 4,289 | 3,664 |
| Operating Expenses | 7,427 | 7,466 | 7,213 | 5,183 | 4,870 |
| Operating Income | 352 | 532 | -1,212 | -894 | -1,206 |
| Interest Expense | 2 | N/A | 5 | -2 | 3 |
| Other Income | 352 | 902 | -3 | 310 | -618 |
| Pre-tax Income | 702 | 1,434 | -1,220 | -582 | -1,827 |
| Income Tax | 418 | 478 | 234 | 214 | 0 |
| Net Income Continuous | 284 | 956 | -1,454 | -796 | -1,827 |
| Minority Interests | -574 | -619 | -313 | -87 | -200 |
| Net Income | $-290 | $337 | $-1,767 | $-883 | $-2,027 |
| EPS Basic Total Ops | -0.07 | 0.07 | -0.33 | -0.20 | -0.46 |
| EPS Basic Continuous Ops | -0.07 | 0.07 | -0.33 | -0.20 | -0.46 |
| EPS Diluted Total Ops | -0.07 | 0.07 | -0.33 | -0.20 | -0.46 |
| EPS Diluted Continuous Ops | -0.07 | 0.07 | -0.33 | -0.20 | -0.46 |
| EBITDA(a) | $713 | $542 | $-1,205 | $-576 | $-1,815 |